ClinicalTrials.gg
CompletedNCT07128888Updated Nov 10, 2026

Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection

A Phase 1 interventional study of GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets in Obesity or Overweight, sponsored by Gan & Lee Pharmaceuticals.. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Gan & Lee Pharmaceuticals. · Phase 1, Interventional, and Treatment

Updated Nov 10, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing bofanglutide in Obesity — 3 open to participants now, 3 under way, 3 of them phase 3. bofanglutide · Obesity.

Enrollment
9th of 15
60 · median 140
Started
2025
with 5 others
Phase 1
7 of 15
none open now
Registered
8th of 15
by date
Lead sponsor
9 of 15
Gan & Lee Pharmaceuticals.

Among the 15 studies testing bofanglutide in Obesity, this one is the 9th largest by enrollment, is one of 6 that started in 2025, is one of 7 in phase 1, and was the 8th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 15 studies testing bofanglutide in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About bofanglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing bofanglutide in Obesity, or all of them as a file.
02

Study summary

This is a single-center, open-label, fixed-sequence phase I clinical study to evaluate the effect of GZR18 Injection on gastric emptying and the effect of repeated SC injections of GZR18 Injection on the pharmacokinetics of oral digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets.

A total of 60 obese or overweight subjects are planned to be enrolled, with no less than one-quarter of the subjects from either gender.

The study duration for each subject in this study is approximately 26 weeks: including a screening period of up to 4 weeks (W-28 to D-1), single-drug administration and dose escalation stages of 16 weeks (W1D1 to W16D7) and the combined drug administration stage of 6 weeks (W17D1 to W23D1)

03

Conditions studied

  • Obesity or Overweight
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Obese Chinese subjects, who voluntarily sign the Form (ICF), can receive SC injection, fully understand the content, process and possible adverse reactions of the trial, and are able to follow the regulations on and restrictions specified in this protocol.

    2. Male or female, 18 to 50 years of age at signing the ICF (both inclusive).

    3. (BMI) within 26-35 kg/m2 (both ends inclusive) at screening.

    4. No abnormality or not abnormality as judged by the investigator in physical examination, vital signs, routine laboratory tests (hematology, blood chemistry, urinalysis, thyroid function and coagulation), 12-lead , ultrasonography of liver, gallbladder, pancreas, and spleen + both kidneys, chest imaging examination and other results. (abnormal indicators related to obesity or overweight, and the investigator assesses that they have no impact on this study, they can be enrolled)

    5. Subjects of with no birth plan from the signing of the ICF to 8 weeks after the last dose, willingness to take effective measures, and no plan for sperm or ovum donation. Females of childbearing potential must not be lactating and must have negative results for blood pregnancy test at screening (including D-1).

Exclusion criteria

Exclusion Criteria:

  • 1.Subjects with a previous or existing history of heart, liver, kidney, gastrointestinal tract, respiratory system, nervous system, psychiatric disorders, endocrine diseases (except obesity), malignant tumors and other diseases that are judged by the investigator to have an impact on the evaluation of the results of this study.

    2. History or existing diseases that increase the risk of subjects, such as hypoglycemia, acute or chronic pancreatitis, pancreatic injury, history of symptomatic gallbladder disease; cholelithiasis with high risk of acute biliary pancreatitis at screening (e.g., silt-like lithiasis, gallbladder or bile duct stone ≤ 5 mm in diameter),newly diagnosed cholecystitis at screening.

    3. Subjects with previous or existing digestive system diseases who are judged unsuitable for the study by the investigator, such as history of active peptic ulcer or hemorrhage, inflammatory bowel disease, abnormal gastric emptying (such as gastric paresis or pyloric stenosis, gastric outlet obstruction), continuous use of drugs affecting gastrointestinal motility for ≥ 1 week (including but not limited to domperidone, mosapride, macrolides), and acute hemorrhoidal attacks within the past three months.

    4. History or family history of previous or existing medullary thyroid carcinoma, multiple endocrine neoplasia type 2.

    5. Subjects who have used any drugs that alter the activity of drug metabolizing enzymes or transporters within 4 weeks prior to screening, or subjects with acute diseases or concomitant medication from the screening period to before administration of the medicinal product (IMP).

    6. Subjects with severe infection or unexplained infection within 4 weeks before screening.

    7. Major surgery within 6 months prior to screening, or scheduled surgery or hospitalization during the study.

    8. Subjects with allergic constitution prior to screening, or a history of bronchial asthma, eczema and other allergic diseases (except mild seasonal allergy), or a history of severe food allergy (such as laryngeal edema, shock), or known allergy to any ingredient in investigational medicinal products (IMPs) [GLP-1 receptor (GLP-1R) agonist, paracetamol, digoxin, rosuvastatin, warfarin and their ].

    9. Use of any prescription drugs, over-the-counter drugs or Chinese herbal medicines within 2 weeks prior to screening; or use of any GLP-1R agonists or drugs with the same mechanism of action to GLP-1R agonists [such as GLP-1R/glucagon receptor (GCGR) agonists or gastric inhibitory polypeptide receptor (GIPR)/GLP-1R agonists or GIPR/GLP-1R/GCGR agonists] within 6 months prior to screening; or use of any weight loss drugs within 6 months prior to screening.

    10. Subjects who have been vaccinated within 1 month before screening or are scheduled for vaccination during the study.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    GZR18 injection

    Drug: GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets

Interventions

  • DrugGZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets

    Drug pages: Bofanglutide · Digoxin · Rosuvastatin · Warfarin

    GZR18 injection: 3 mg-36 mg,16 weeks; Warfarin Sodium Tablets:2.5mg,twice; Rosuvastatin Calcium Tablets:10mg,twice; Digoxin Tablets:0.25mg,twice

06

What researchers measure

Primary outcomes

  1. Cmax:Maximum plasma concentration

    Time frame: through study completion,up to 16 weeks

  2. AUC0-last:Area under the plasma concentration-time curve at 0 h to last observation time-point after a single dose.

    Time frame: through study completion,up to 16 weeks

  3. AUC0-inf:Area under the plasma concentration-time curve at 0 h to infinity after a single dose.

    Time frame: through study completion,up to 16 weeks

Secondary outcomes

  1. Tmax:Time of Maximum Drug Concentration

    Time frame: through study completion,up to 16 weeks

  2. t1/2: Elimination half-life

    Time frame: through study completion,up to 16 weeks

  3. CL/F: Apparent clearance rate

    Time frame: through study completion,up to 16 weeks

  4. Vz/F:Apparent Volume of Distribution associated with the Terminal Phase following Oral Administration

    Time frame: through study completion,up to 16 weeks

  5. PD:Area under the international normalized ratio-time curve (INRAUC) and maximum international normalized ratio postdose (INRMAX) for warfarin

    Time frame: through study completion,up to 16 weeks

07

Study locations

1 site
  • Study site 01
    Beijing, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Apr 2026, 6 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 6 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Nov 2025 → Sep 2025, primary completion Jul 2026 → Apr 2026 and completion Jul 2026 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Aug 19, 2025
StartActual
Sep 24, 2025was Nov 2025
Primary completionActual
Apr 13, 2026was Jul 2026
CompletionActual
Apr 13, 2026was Jul 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 10, 2026
Start date
Nov 17, 2025→Sep 24, 2025
Nov 10, 2026
Primary completion
Jul 5, 2026→Apr 13, 2026 (actual)
Nov 10, 2026
Study completion
Jul 5, 2026→Apr 13, 2026 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Recruiting→Completed
    Start date Nov 17, 2025→Sep 24, 2025
    Primary completion Jul 5, 2026→Apr 13, 2026 (now actual)
    Study completion Jul 5, 2026→Apr 13, 2026 (now actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07128888
Responsible party
Sponsor
First posted
Aug 19, 2025
Start date
Sep 24, 2025
Primary completion
Apr 13, 2026
Completion
Apr 13, 2026
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bofanglutide · Digoxin · Rosuvastatin · Warfarin

Start the discussion